Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Depreciation and Depletion (2020 - 2023)

Rein Therapeutics filings provide 4 years of Depreciation and Depletion readings, the most recent being $12000.0 for Q4 2023.

  • For the quarter ending Q4 2023, Depreciation and Depletion fell 90.4% year-over-year to $12000.0, compared with a TTM value of $49000.0 through Dec 2023, down 71.01%, and an annual FY2023 reading of $49000.0, down 71.01% over the prior year.
  • Depreciation and Depletion hit $12000.0 in Q4 2023 for Rein Therapeutics, roughly flat from $12000.0 in the prior quarter.
  • The five-year high for Depreciation and Depletion was $125000.0 in Q4 2022, with the low at $2000.0 in Q1 2021.
  • Median Depreciation and Depletion over the past 4 years was $14000.0 (2020), compared with a mean of $32312.5.
  • The largest YoY upside for Depreciation and Depletion was 960.0% in 2021 against a maximum downside of 97.14% in 2021.
  • Year by year, Depreciation and Depletion stood at $10000.0 in 2020, then soared by 960.0% to $106000.0 in 2021, then grew by 17.92% to $125000.0 in 2022, then plummeted by 90.4% to $12000.0 in 2023.
  • According to Business Quant data, Depreciation and Depletion over the past three periods came in at $12000.0, $12000.0, and $12000.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.